Pharmaceutical Industry Trends | Healthcare Trends

Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.

How it helps

With In Vivo, you’ll benefit from:

Insight about the key players in the industry
In-depth coverage of company strategies
Expert analysis of deal making, R&D, commercial, market access and finance strategies and trends
Exclusive insider insight and thought leadership
Help with specific questions from our renowned Ask-the-Analyst™ service

How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.

Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.

Start a free trial

In Vivo

Rising Leaders 2021

Gain insights into managing unexpected events, effectively communicating change, executing crisis management plans, and more. Industry experts share their insights into innovative ways to integrate teams after M&A, manage D&I initiatives, and build strong leadership for a changing workforce.

In Vivo, Pink Sheet

Manufacturing and Distribution: Challenges and Opportunities

The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

In Vivo

COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020

A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.

In Vivo

Pandemic Puts A Spotlight On Counterfeit Drugs

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

In Vivo

The 14 Billion Dose COVID-19 Manufacturing Challenge

Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.

In Vivo

Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

In Vivo

Deal Making Trends 2021

Despite the chaos felt in many other sectors during the COVID-19 pandemic, pharma IPOs experienced a banner year in 2020. Understand deal making trends and business strategies as In Vivo examines the emergence of special purpose acquisition companies (SPACs) in a data-packed infographic

In Vivo

At War With A Pandemic: Manufacturing For Our Lives

The rapid development of a vaccine to fight COVID-19 is an effort that will be discussed and admired for centuries to come. The effort to make and deliver the vaccines to those who are most at risk is a battle all of its own. Two manufacturers talk to In Vivo about managing roll out strategies when the whole world is watching.

In Vivo

Pandemic Perspectives: Pharma Must Not Let Its COVID-19 Halo Slip

Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.

In Vivo

The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.

In Vivo

Pharma Intelligence Insights – Outlook 2021 Report

Power your strongest strategy for the year ahead with insights from the Outlook 2021 report. A combination of Scrip’s Scrip 100, Medtech Insight’s Medtech 100, and In Vivo’s Outlook reports, Outlook 2021 is a comprehensive window into the key trends, challenges and opportunities impacting the biopharma, medtech, and generics sectors for the year to come.

In Vivo

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

In Vivo

How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.

In Vivo

From US To EU: Young Biotechs Going It Alone

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

In Vivo

FDA Emphasizes Clinical Trial Flexibility During Coronavirus Pandemic

FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause.

In Vivo: strategic insights for life sciences decision-makers

Strategic industry insight

What's included

Below are the feature list

Cutting edge thought leadership

Expert analysis

Hear from news makers

Ask the expert

In depth examination of deal-making and finance strategies

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

William Looney

Editor, Executive Editor, In Vivo

Cathy Kelly

Editor, Senior editor

Denise Peterson

Management, Editor In Chief, Pharma US

Related Products

Datamonitor Healthcare: data analysis and insight

Pink Sheet

Pharmaprojects

Next steps

This is Contactus Section

Request a Trial

How can we help you?

Pharma Report Store